Sign inJoin waitlistJoin the waitlist

Boyu Hu

Director of Lymphoma and Chronic Lymphocytic Leukemia · Univ of Utah Sch of Med

Credentials: · · · · · · ·

History

Univ of Utah Sch of Med
Present
Univ of Utah Sch of Med
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2015–2018
Hospital of the University of Pennsylvania
2012–2015
Case Western Reserve University School of Medicine
2008–2012
Duke University

Research

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
New England Journal of Medicine · 2024 · 205 citations
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Journal of the National Comprehensive Cancer Network · 2021 · 132 citations
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Journal of the National Comprehensive Cancer Network · 2023 · 117 citations

Deborah Stephens
11 papers
Harsh Shah
11 papers
Daniel Ermann
8 papers · 4 as a fellow
Lindsey Fitzgerald
7 papers · 5 as a resident
Stephen Smith
6 papers
Victoria Vardell
6 papers · 3 as a fellow
Ann LaCasce
5 papers
Daniel Landsburg
5 papers
Francisco Hernandez-Ilizaliturri
5 papers
Joseph Tuscano
5 papers
Nancy Bartlett
5 papers
Paolo Caimi
5 papers

Grants

Targeting Lymphoma: A Multimodal Approach Using Radiation, CART-19 Therapy, and Gut Microbiome Modulation
National Cancer Institute · R01
PI · $1.3M · University of Pennsylvania
2025–2029
Efforts to Discover Novel Therapies and Reduce Treatment Toxicities for Lymphoma and Chronic Lymphocytic Leukemia Patients Through Collaboration and the NCTN
National Cancer Institute · R50
Contact PI · $935.1K · Utah State Higher Education System--University of Utah
2025–2029

Clinical trials

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
Principal investigator · Not yet recruiting · Phase 2
SWOG Cancer Research Network
2026–2035
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
Principal investigator · Terminated · Phase 1, Phase 2
University of Utah
2022–2025
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Principal investigator · Active not recruiting · Phase 1
Catherine Bollard
2019–2026
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031